Klotho inhibits angiotensin II-induced cardiomyocyte hypertrophy through suppression of the AT1R/beta catenin pathway

Myocardial hypertrophy is an independent risk factor for cardiac morbidity and mortality. The antiaging protein klotho reportedly possesses a protective role in cardiac diseases. However, the precise mechanisms underlying the cardioprotective effects of klotho remain unknown. This study was aimed to determine the effects of klotho on angiotensin II (Ang II)-induced hypertrophy in neonatal rat cardiomyocytes and the possible mechanism of actions. We found that klotho significantly inhibited Ang II induced hypertrophic growth of neonatal cardiomyocytes, as evidenced by decreased [H-3]-Leucine incorporation, cardiomyocyte surface area and beta-myosin heavy chain (beta-MHC) mRNA expression. Meanwhile, klotho inhibited Ang II stimulated activation of the Wnt/beta-catenin pathway in cardiomyocytes, as evidenced by decreased protein expression of active beta-catenin, downregulated protein and mRNA expression of the beta-catenin target genes c-myc and cyclin D1, and increased beta-catenin phosphorylation. Inhibition of the Wnt/beta-catenin pathway by the specific inhibitor XAV939 markedly attenuated Ang II -induced cardiomyocyte hypertrophy. The further study revealed that klotho treatment significantly downregulated protein expression of Ang II receptor type I (AT(1)R) but not type II (AT(2)R). The AT(1)R antagonist losartan inhibited Ang II stimulated activation of the Wnt/beta-catenin pathway and cardiomyocyte hypertrophy. Our findings suggest that klotho inhibits Ang II -induced cardiomyocyte hypertrophy through suppression of the AT(1)R/beta-catenin signaling pathway, which may provide new insights into the mechanism underlying the protective effects of klotho in heart diseases, and raise the possibility that klotho may act as an endogenous antihypertrophic factor by inhibiting the Ang II signaling pathway. (C) 2016 Elsevier Inc. All rights reserved.